Scarica l'app Stockscreener
469.21
2.04%
-9.75
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché TMO Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$478.96
Aprire:
$480
Volume 24 ore:
1.43M
Relative Volume:
0.64
Capitalizzazione di mercato:
$174.37B
Reddito:
$45.20B
Utile/perdita netta:
$6.88B
Rapporto P/E:
25.79
EPS:
18.1925
Flusso di cassa netto:
$6.75B
1 W Prestazione:
-0.11%
1M Prestazione:
-5.12%
6M Prestazione:
-17.30%
1 anno Prestazione:
+11.75%
Intervallo 1D:
$468.10
$481.83
Intervallo di 1 settimana:
$461.00
$481.83
Portata 52W:
$385.46
$643.99
Thermo Fisher Scientific Inc Stock (TMO) Company Profile
Nome
Thermo Fisher Scientific Inc
Settore
Industria
Telefono
(781) 622-1000
Indirizzo
168 THIRD AVENUE, WALTHAM, MA
Compare TMO vs DHR, IDXX, A, WAT
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TMO
Thermo Fisher Scientific Inc
|
469.21 | 174.37B | 45.20B | 6.88B | 6.75B | 18.19 |
DHR
Danaher Corp
|
175.15 | 123.97B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
567.46 | 45.07B | 4.30B | 1.06B | 1.04B | 13.08 |
A
Agilent Technologies Inc
|
114.52 | 32.36B | 7.07B | 1.29B | 993.00M | 4.5355 |
WAT
Waters Corp
|
307.12 | 30.15B | 3.17B | 642.63M | 516.49M | 10.77 |
Thermo Fisher Scientific Inc Stock (TMO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-27 | Iniziato | DZ Bank | Buy |
| 2025-12-11 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-12-09 | Iniziato | Goldman | Buy |
| 2025-12-08 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2025-12-02 | Ripresa | Morgan Stanley | Overweight |
| 2025-12-01 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2025-09-11 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2025-08-19 | Iniziato | William Blair | Outperform |
| 2025-07-24 | Downgrade | HSBC Securities | Buy → Hold |
| 2025-07-11 | Aggiornamento | Scotiabank | Sector Perform → Sector Outperform |
| 2025-07-09 | Downgrade | UBS | Buy → Neutral |
| 2025-01-10 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2024-12-23 | Iniziato | Scotiabank | Sector Perform |
| 2024-10-14 | Iniziato | Redburn Atlantic | Buy |
| 2024-10-01 | Iniziato | Stephens | Overweight |
| 2024-08-28 | Iniziato | Wells Fargo | Overweight |
| 2024-06-03 | Ripresa | Jefferies | Buy |
| 2024-03-18 | Ripresa | Citigroup | Neutral |
| 2024-01-24 | Downgrade | Barclays | Overweight → Equal Weight |
| 2024-01-08 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2023-12-18 | Iniziato | HSBC Securities | Buy |
| 2023-12-13 | Iniziato | Wolfe Research | Outperform |
| 2023-10-26 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2023-10-25 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2023-09-28 | Iniziato | Bernstein | Outperform |
| 2023-09-06 | Ripresa | Citigroup | Buy |
| 2023-07-19 | Iniziato | Raymond James | Outperform |
| 2023-07-19 | Reiterato | Robert W. Baird | Outperform |
| 2023-07-13 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2023-04-04 | Reiterato | Barclays | Overweight |
| 2022-12-14 | Iniziato | Deutsche Bank | Buy |
| 2022-12-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-10-27 | Downgrade | The Benchmark Company | Buy → Hold |
| 2022-08-25 | Iniziato | Credit Suisse | Neutral |
| 2022-04-25 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| 2022-01-26 | Ripresa | Barclays | Overweight |
| 2021-10-20 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-08-05 | Ripresa | Credit Suisse | Outperform |
| 2021-07-16 | Iniziato | The Benchmark Company | Buy |
| 2021-03-18 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-03-03 | Iniziato | Barclays | Overweight |
| 2021-01-08 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2020-12-16 | Downgrade | Citigroup | Buy → Neutral |
| 2020-12-02 | Iniziato | Goldman | Buy |
| 2020-11-10 | Iniziato | KeyBanc Capital Markets | Sector Weight |
| 2020-09-30 | Iniziato | Atlantic Equities | Overweight |
| 2020-09-14 | Iniziato | Morgan Stanley | Overweight |
| 2020-08-20 | Ripresa | JP Morgan | Overweight |
| 2020-07-15 | Aggiornamento | Cleveland Research | Neutral → Buy |
| 2020-07-07 | Reiterato | Needham | Buy |
| 2020-04-23 | Reiterato | Needham | Buy |
| 2020-01-31 | Reiterato | Needham | Buy |
| 2020-01-22 | Iniziato | Credit Suisse | Neutral |
| 2020-01-08 | Iniziato | Wells Fargo | Equal Weight |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2019-11-15 | Iniziato | Stifel | Buy |
| 2019-07-25 | Reiterato | Needham | Buy |
| 2019-07-16 | Downgrade | Needham | Strong Buy → Buy |
| 2019-05-30 | Iniziato | Wolfe Research | Outperform |
| 2019-05-23 | Reiterato | Needham | Strong Buy |
| 2019-04-22 | Reiterato | Needham | Strong Buy |
| 2019-04-16 | Reiterato | BofA/Merrill | Buy |
Mostra tutto
Thermo Fisher Scientific Inc Borsa (TMO) Ultime notizie
Thermo Fisher Scientific Q1 2026 Financial Results and SEC 10-Q Filing Summary - Minichart
Argus Adjusts Price Target on Thermo Fisher Scientific to $560 From $610 - marketscreener.com
Billionaire Investor Takes New Stake In Thermo Fisher Scientific - Yahoo Finance
Thermo Fisher (NYSE: TMO) grows Q1 revenue and closes $9.1B Clario deal - Stock Titan
How Investors Are Reacting To Thermo Fisher Scientific (TMO) Expanding Its U.S. Bioprocess Design Center - Yahoo Finance
Argus Cuts Price Target on Thermo Fisher Scientific to $560 From $610 - marketscreener.com
Vanguard (NYSE: TMO) reports 28.0M shares of Thermo Fisher, 7.53% stake - Stock Titan
Pharmaceutical Contract Development and Manufacturing Organization (CDMO) for Formulations Market Research Report 2026: Opportunities, Trends, Competitive Landscape, Strategies, Forecasts 2020-2035 - GlobeNewswire Inc.
Thermo Fisher Scientific opens bioprocess design center in Massachusetts - chemengonline.com
Soil Testing Equipment Market Size, Share & Growth Outlook - openPR.com
Thermo Fisher Scientific Agrees to Divest Its Microbiology Business to Astorg - ChemAnalyst
PowerFlex thermal cycler boosts PCR flexibility & speed - SelectScience
Molecular Quality Controls Market | THERMO FISHER SCIENTIFIC, INC, Qnostics, Zeptometrix Corporation etc. - openPR.com
Insider Sell: Gianluca Pettiti Sells Shares of Thermo Fisher Sci - GuruFocus
Thermo Fisher Scientific president & COO sells $185,064 in stock By Investing.com - Investing.com UK
Thermo Fisher (NYSE: TMO) COO executes 400-share Rule 10b5-1 sale - Stock Titan
Thermo Fisher Scientific to sell its microbiology business as Astorg - chemengonline.com
Thermo Fisher Scientific launches applied Biosystems PowerFlex Thermal Cycler - Med-Tech Insights
Thermo Fisher Scientific, SHL Medical Collaborate on Integrated Drug-Device Solutions - Medical Product Outsourcing
Do You Believe in The Long-Term Growth Outlook of Thermo Fisher Scientific (TMO)? - Insider Monkey
Thermo Fisher Scientific Opens U.S. Flagship Bioprocess Design Center to Accelerate the Delivery of Life-changing Therapies - BioSpace
Thermo Fisher Scientific to Host Investor DayApril 28, 2026 - BioSpace
Thermo Fisher to Sell Microbiology Business to Astorg - WSJ
Thermo Fisher opens Plainville design center amid $2B push for U.S. manufacturing - The Business Journals
Thermo Fisher sells microbiology business for $1B - BioWorld News
Thermo Fisher agrees to sell microbiology business to Astorg in $1bn deal - Medical Device Network
Thermo Fisher Scientific Opens U.S. Flagship Bioprocess Design Center to Accelerate the Delivery of - PharmiWeb.com
Thermo Fisher inks $1.1B deal to sell microbiology unit to Astorg - MedTech Dive
Thermo Fisher Scientific Opens Flagship U.S. Bioprocess Design Center in MA - Contract Pharma
Thermo Fisher Stock Fell After Q1 2026 Earnings. Is TMO a Buy? - TIKR.com
Medical Refrigerators Market Competitive Analysis to 2028 | - openPR.com
Thermo Fisher drops despite Q1 beat, guidance hike - MSN
Thermo Fisher sells microbiology biz to Astorg for $1.075 B - BioSpectrum Asia
Thermo Fisher Scientific Signs Agreement to Sell its Microbiology Business to Astorg - BioSpace
Thermo Fisher to divest microbiology business in $1.07 billion deal with PE firm Astorg - DOTmed
Thermo Fisher sells microbiology business to private equity firm for $1B - The Business Journals
Thermo Fisher to sell microbiology business to PE firm Astorg for over $1 billion - MSN
Thermo Fisher Scientific Inc (TMO) Stock Price, Trades & News - GuruFocus
Thermo Fisher Scientific (TMO) Sells Microbiology Business for $1.075 Billion - GuruFocus
Morgan Stanley Maintains Thermo Fisher Scientific(TMO.US) With Buy Rating, Cuts Target Price to $620 - Moomoo
Morgan Stanley Lowers Price Target on Thermo Fisher Scientific to $620 From $670, Keeps Overweight Rating - marketscreener.com
Thermo Fisher selling microbiology business to Astorg for $1.08B - Yahoo Finance
Astorg III, FCPR, managed by Astorg Asset Management S A.R.L. signed a definitive agreement to acquire Global Microbiology Business from Thermo Fisher Scientific Inc. for approximately $1.1 billion. - marketscreener.com
Latham Advises Astorg in Acquisition of Thermo Fisher Scientific Global Microbiology Business - Latham & Watkins LLP
[144] THERMO FISHER SCIENTIFIC INC. SEC Filing - Stock Titan
Thermo Fisher (TMO) Sells Microbiology Business for $1.075 Billi - GuruFocus
Thermo Fisher Buys into Astorg - Baystreet.ca
Luxembourg: Astorg to acquire Thermo Fisher Scientific’s microbiology business for US$1.075bn - Investors in Healthcare
Thermo Fisher to sell microbiology unit to Astorg for $1.08 billion By Investing.com - Investing.com Canada
Thermo Fisher to sell microbiology unit to Astorg for $1.08 billion - Investing.com
Thermo Fisher Scientific signs agreement to sell its microbiology business to Astorg - marketscreener.com
Thermo Fisher Scientific Inc Azioni (TMO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.12%
1.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):